Neena Brizmohun
Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Latest From Neena Brizmohun
Kite Strikes CAR-T Access & Discount Deal For Tecartus In England
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Another EU Filing Targets Burgeoning NMOSD Market
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Big Changes Kicking In Under Australia’s Personalized Medical Devices Rules
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.
New UK Rare Disease Framework Seeks To Reduce ‘Diagnostic Odyssey’ For Patients
England, Scotland, Wales and Northern Ireland will publish their respective action plans to deliver the aims of the UK’s new framework for rare diseases.